TCR-T immunotherapy for the treatment of solid tumor: current status, challenges and future prospects

Weitao ZHENG; Hanluo LI; Kanghong HU

doi:10.19401/j.cnki.1007-3639.2023.07.009

您当前的位置：

首页 >

文章列表页 >

TCR-T immunotherapy for the treatment of solid tumor: current status, challenges and future prospects

Review | 更新时间：2025-12-31

- TCR-T immunotherapy for the treatment of solid tumor: current status, challenges and future prospects
- China Oncology Vol. 33, Issue 7, Pages: 707-716(2023)
- 作者机构：
  
  湖北工业大学中德生物医学中心，工业发酵省部共建协同创新中心，国家外专局/教育部细胞调控与分子药物“111”引智基地，湖北武汉 430068
- 作者简介：
  
  HU Kanghong.
- 基金信息：
- DOI：10.19401/j.cnki.1007-3639.2023.07.009
  CLC： R730.51
- Received：01 August 2022，
  
  Revised：2023-02-15，
  
  Published：30 July 2023
- 稿件说明：
移动端阅览
Weitao ZHENG, Hanluo LI, Kanghong HU. TCR-T immunotherapy for the treatment of solid tumor: current status, challenges and future prospects[J]. China Oncology, 2023, 33(7): 707-716.
DOI：

Weitao ZHENG, Hanluo LI, Kanghong HU. TCR-T immunotherapy for the treatment of solid tumor: current status, challenges and future prospects[J]. China Oncology, 2023, 33(7): 707-716. DOI： 10.19401/j.cnki.1007-3639.2023.07.009.

摘要

T细胞受体工程T细胞（engineered T cell receptor-T cell，TCR-T）疗法和嵌合抗原受体T细胞（chimeric antigens receptor-T cell，CAR-T）疗法是目前过继性T细胞治疗最有效的两种方式。由于CAR仅能识别肿瘤表面的抗原，在实体瘤治疗中至今未有令人满意的结果。TCR不仅能识别肿瘤表面抗原，同时能识别胞内抗原，因此，TCR-T疗法在治疗实体瘤方面显示出前所未有的前景，成为极具潜力的治疗方式。本综述探讨了TCR-T疗法与CAR-T疗法识别癌症抗原机制的差异及当前TCR-T疗法靶向的临床靶点和不同类型的肿瘤抗原，描述了TCR-T抗肿瘤治疗的临床开发现状，并讨论了临床前评估TCR效价的标准和目前TCR-T治疗的优势、存在的局限性及可能有效的应对措施。最后，我们回顾了TCR-T治疗的现状和当前仍存在的一些挑战，强调靶向肿瘤特异性抗原的重要性，概述了结合检查点阻断治疗和溶瘤病毒等的新抗原特异性TCR-T治疗策略，以期这种联合治疗能够显著改善癌症的免疫治疗效果，并对未来TCR-T治疗根除多发性癌症提供一些思路。

Abstract

Engineered T cell receptor-T cell (TCR-T) therapy and chimeric antigen receptor-T cell (CAR-T) therapy are currently the two most effective ways of adoptive T cell therapy. Because CAR can only recognize antigens on the surface of tumors

CAR-T therapy has not yet had satisfactory results in the treatment of solid tumors. TCR can not only recognize tumor surface antigens

but also intracellular antigens. Thus TCR-T therapy has shown unprecedented promise in the treatment of solid tumors

and has become an extremely attractive treatment modality. This review described the differences between TCR-T therapy and CAR-T therapy in recognizing cancer antigens

the clinical targets and different types of tumor antigens targeted by current TCR-T therapy

the clinical development status of TCR-T antitumor therapy

and discussed the criteria for preclinical evaluation of TCR titer and the advantages

limitations and possible effective countermeasures of current TCR-T therapy. Finally

we reviewed the current status of TCR-T therapy and some of the challenges

emphasized the importance of targeting tumor-specific antigens

and outlined neoantigen-specific TCR-T treatment strategies combining checkpoint blockage therapy and oncolytic viruses

which we expect will significantly improve cancer immunotherapy and provide some clues for future TCR-T therapy to eradicate multiple types of cancer.

关键词

Keywords

references

MO Z M , DU P X , WANG G P , et al . The multi-purpose tool of tumor immunotherapy: gene-engineered T cells [J ] . J Cancer , 2017 , 8 ( 9 ): 1690 - 1703 . DOI: 10.7150/jca.18681 http://doi.org/10.7150/jca.18681

SCOTT L J . Osimertinib as first-line therapy in advanced NSCLC: a profile of its use [J ] . Drugs Ther Perspect , 2018 , 34 ( 8 ): 351 - 357 . DOI: 10.1007/s40267-018-0536-9 http://doi.org/10.1007/s40267-018-0536-9

WEBER E W , MAUS M V , MACKALL C L . The emerging landscape of immune cell therapies [J ] . Cell , 2020 , 181 ( 1 ): 46 - 62 . DOI: S0092-8674(20)30263-4 http://doi.org/S0092-8674(20)30263-4

JIANG X T , XU J , LIU M F , et al . Adoptive CD8 + T cell therapy against cancer: challenges and opportunities [J ] . Cancer Lett , 2019 , 462 : 23 - 32 . DOI: 10.1016/j.canlet.2019.07.017 http://doi.org/10.1016/j.canlet.2019.07.017 https://linkinghub.elsevier.com/retrieve/pii/S0304383519304136 https://linkinghub.elsevier.com/retrieve/pii/S0304383519304136

SALTER A I , RAJAN A , KENNEDY J J , et al . Comparative analysis of TCR and CAR signaling info rms CAR designs with superior antigen sensitivity and in vivo function [J ] . Sci Signal , 2021 , 14 ( 697 ): eabe2606 . DOI: 10.1126/scisignal.abe2606 http://doi.org/10.1126/scisignal.abe2606 https://www.science.org/doi/10.1126/scisignal.abe2606 https://www.science.org/doi/10.1126/scisignal.abe2606

XU Y Y , YANG Z Y , HORAN L H , et al . A novel antibody-TCR (AbTCR) platform combines Fab-based antigen recognition with gamma/delta-TCR signaling to facilitate T-cell cytotoxicity with low cytokine release [J ] . Cell Discov , 2018 , 4 : 62 . DOI: 10.1038/s41421-018-0066-6 http://doi.org/10.1038/s41421-018-0066-6

GARBER K . Driving T-cell immunotherapy to solid tumors [J ] . Nat Biotechnol , 2018 , 36 ( 3 ): 215 - 219 . DOI: 10.1038/nbt.4090 http://doi.org/10.1038/nbt.4090

CHAPUIS A G , EGAN D N , BAR M , et al . T cell receptor gene therapy targeting WT1 prevents acute myeloid leukemia relapse post-transplant [J ] . Nat Med , 2019 , 25 ( 7 ): 1064 - 1072 . DOI: 10.1038/s41591-019-0472-9 http://doi.org/10.1038/s41591-019-0472-9

BLÜTHMANN H , KISIELOW P , UEMATSU Y , et al . T-cell-specific deletion of T-cell receptor transgenes allows functional rearrangement of endogenous alpha- and beta-genes [J ] . Nature , 1988 , 334 ( 6178 ): 156 - 159 . DOI: 10.1038/334156a0 http://doi.org/10.1038/334156a0

BUONAGURO L , TAGLIAMONTE M . Selecting target antigens for cancer vaccine development [J ] . Vaccines (Basel) , 2020 , 8 ( 4 ): 615 .

ZHANG J X , WANG L Y . The emerging world of TCR-T cell trials against cancer: a systematic review [J ] . Technol Cancer Res Treat , 2019 , 18 : 1533033819831068.

ZHAO Q J , JIANG Y , XIANG S X , et al . Engineered TCR-T cell immunotherapy in anticancer precision medicine: pros and cons [J ] . Front Immunol , 2021 , 12 : 658753 . DOI: 10.3389/fimmu.2021.658753 http://doi.org/10.3389/fimmu.2021.658753 https://www.frontiersin.org/articles/10.3389/fimmu.2021.658753/full https://www.frontiersin.org/articles/10.3389/fimmu.2021.658753/full

HELLMAN L M , FOLEY K C , SINGH N K , et al . Improving T cell receptor on-target specificity via structure-guided design [J ] . Mol Ther , 2019 , 27 ( 2 ): 300 - 313 . DOI: S1525-0016(18)30594-X http://doi.org/S1525-0016(18)30594-X

TAWARA I , KAGEYAMA S , MIYAHARA Y , et al . Safety and persistence of WT1-specific T-cell receptor gene-transduced lymphocytes in patients with AML and MDS [J ] . Blood , 2017 , 130 ( 18 ): 1985 - 1994 . DOI: 10.1182/blood-2017-06-791202 http://doi.org/10.1182/blood-2017-06-791202

ROBBINS P F , MORGAN R A , FELDMAN S A , et al . Tumor regression in patients with metastatic synovial cell sarcoma and melanoma using genetically engineered lymphocytes reactive with NY-ESO-1 [J ] . J Clin Oncol , 2011 , 29 ( 7 ): 917 - 924 . DOI: 10.1200/JCO.2010.32.2537 http://doi.org/10.1200/JCO.2010.32.2537

MORGAN R A , CHINNASAMY N , ABATE-DAGA D , et al . Cancer regression and neurological toxicity following anti-MAGE-A3 TCR gene therapy [J ] . J Immunother , 2013 , 36 ( 2 ): 133 - 151 . DOI: 10.1097/CJI.0b013e3182829903 http://doi.org/10.1097/CJI.0b013e3182829903

CAMERON B J , GERRY A B , DUKES J , et al . Identification of a Titin-derived HLA-A1-presented peptide as a cross-reactive target for engineered MAGE A3-directed T cells [J ] . Sci Transl Med , 2013 , 5 ( 197 ): 197ra103 .

YE B X , STARY C M , GAO Q P , et al . Genetically modified T-cell-based adoptive immunotherapy in hematological malignancies [J ] . J Immunol Res , 2017 , 2017 : 5210459 .

LIM W A , JUNE C H . The principles of engineering immune cells to treat cancer [J ] . Cell , 2017 , 168 ( 4 ): 724 - 740 . DOI: S0092-8674(17)30064-8 http://doi.org/S0092-8674(17)30064-8

MOORE A R , ROSENBERG S C , MCCORMICK F , et al . RAS-targeted therapies: is the undruggable drugged? [J ] . Nat Rev Drug Discov , 2020 , 19 ( 8 ): 533 - 552 . DOI: 10.1038/s41573-020-0068-6 http://doi.org/10.1038/s41573-020-0068-6

WANG Q J , YU Z Y , GRIFFITH K , et al . Identification of T-cell receptors targeting KRAS -mutated human tumors [J ] . Cancer Immunol Res , 2016 , 4 ( 3 ): 204 - 214 . DOI: 10.1158/2326-6066.CIR-15-0188 http://doi.org/10.1158/2326-6066.CIR-15-0188 https://aacrjournals.org/cancerimmunolres/article/4/3/204/468486/Identification-of-T-cell-Receptors-Targeting-KRAS https://aacrjournals.org/cancerimmunolres/article/4/3/204/468486/Identification-of-T-cell-Receptors-Targeting-KRAS

MAOZ A , RENNERT G , GRUBER S B . T-cell transfer therapy targeting mutant KRAS [J ] . N Engl J Med , 2017 , 376 ( 7 ): e11 . DOI: 10.1056/NEJMc1616637 http://doi.org/10.1056/NEJMc1616637 http://www.nejm.org/doi/10.1056/NEJMc1616637 http://www.nejm.org/doi/10.1056/NEJMc1616637

DESAI J , GAN H , BARROW C , et al . Phase Ⅰ, open-label, dose-escalation/dose-expansion study of lifirafenib (BGB-283), an RAF family kinase inhibitor, in patients with solid tumors [J ] . J Clin Oncol , 2020 , 38 ( 19 ): 2140 - 2150 . DOI: 10.1200/JCO.19.02654 http://doi.org/10.1200/JCO.19.02654 https://ascopubs.org/doi/10.1200/JCO.19.02654 https://ascopubs.org/doi/10.1200/JCO.19.02654

HOOGEVEEN R C , ROBIDOUX M P , SCHWARZ T , et al . Phenotype and function of HBV-specific T cells is determined by the targeted epitope in addition to the stage of infection [J ] . Gut , 2019 , 68 ( 5 ): 893 - 904 . DOI: 10.1136/gutjnl-2018-316644 http://doi.org/10.1136/gutjnl-2018-316644

JIN B Y , CAMPBELL T E , DRAPER L M , et al . Engineered T cells targeting E7 mediate regression of human papillomavirus cancers in a murine model [J ] . JCI Insight , 2018 , 3 ( 8 ): e99488 . DOI: 10.1172/jci.insight.99488 http://doi.org/10.1172/jci.insight.99488 https://insight.jci.org/articles/view/99488 https://insight.jci.org/articles/view/99488

NAGARSHETH N B , NORBERG S M , SINKOE A L , et al . TCR-engineered T cells targeting E7 for patients with metastatic HPV-associated epithelial cancers [J ] . Nat Med , 2021 , 27 ( 3 ): 419 - 425 . DOI: 10.1038/s41591-020-01225-1 http://doi.org/10.1038/s41591-020-01225-1

DRAPER L M , KWONG M L M , GROS A , et al . Targeting of HPV-16 + epithelial cancer cells by TCR gene engineered T cells directed against E6 [J ] . Clin Cancer Res , 2015 , 21 ( 19 ): 4431 - 4439 . DOI: 10.1158/1078-0432.CCR-14-3341 http://doi.org/10.1158/1078-0432.CCR-14-3341 https://aacrjournals.org/clincancerres/article/21/19/4431/125533/Targeting-of-HPV-16-Epithelial-Cancer-Cells-by-TCR https://aacrjournals.org/clincancerres/article/21/19/4431/125533/Targeting-of-HPV-16-Epithelial-Cancer-Cells-by-TCR

JOHNSON L A , MORGAN R A , DUDLEY M E , et al . Gene therapy with human and mouse T-cell receptors mediates cancer regression and targets normal tissues expressing cognate antigen [J ] . Blood , 2009 , 114 ( 3 ): 535 - 546 . DOI: 10.1182/blood-2009-03-211714 http://doi.org/10.1182/blood-2009-03-211714

PARKHURST M R , YANG J C , LANGAN R C , et al . T cells targeting carcinoembryonic antigen can mediate regression of metastatic colorectal cancer but induce severe transient colitis [J ] . Mol Ther , 2011 , 19 ( 3 ): 620 - 626 . DOI: 10.1038/mt.2010.272 http://doi.org/10.1038/mt.2010.272

LINETTE G P , STADTMAUER E A , MAUS M V , et al . Cardiovascular toxicity and titin cross-reactivity of affinity-enhanced T cells in myeloma and melanoma [J ] . Blood , 2013 , 122 ( 6 ): 863 - 871 . DOI: 10.1182/blood-2013-03-490565 http://doi.org/10.1182/blood-2013-03-490565

HONG D S , VAN TINE B A , OLSZANSKI A J , et al . Phase Ⅰ dose escalation and expansion trial to assess the safety and efficacy of ADP-A2M4 SPEAR T cells in advanced solid tumors [J ] . J Clin Oncol , 2020 , 38 ( 15_suppl ): 102 .

LAM V K , HONG D S , HEYMACH J , et al . Initial safety assessment of MAGE-A10c796 TCR T-cells in two clinical trials [J ] . J Clin Oncol , 2018 , 36 ( 15_suppl ): 3056 . DOI: 10.1200/JCO.2018.79.1400 http://doi.org/10.1200/JCO.2018.79.1400 https://ascopubs.org/doi/10.1200/JCO.2018.79.1400 https://ascopubs.org/doi/10.1200/JCO.2018.79.1400

DORAN S L , STEVANOVIĆ S , ADHIKARY S , et al . T-cell receptor gene therapy for human papillomavirus-associated epithelial cancers: a first-in-human, phase Ⅰ/Ⅱ study [J ] . J Clin Oncol , 2019 , 37 ( 30 ): 2759 - 2768 . DOI: 10.1200/JCO.18.02424 http://doi.org/10.1200/JCO.18.02424 https://ascopubs.org/doi/10.1200/JCO.18.02424 https://ascopubs.org/doi/10.1200/JCO.18.02424

DAVIS J L , THEORET M R , ZHENG Z L , et al . Development of human anti-murine T-cell receptor antibodies in both responding and nonresponding patients enrolled in TCR gene therapy trials [J ] . Clin Cancer Res , 2010 , 16 ( 23 ): 5852 - 5861 . DOI: 10.1158/1078-0432.CCR-10-1280 http://doi.org/10.1158/1078-0432.CCR-10-1280

KERNEL N N I . TCR-redirected T cells therapy in patient with HBV related HCC [J ] . Case Med Res , 2019 .[Epub ahead of print ] .

SPEAR T T , EVAVOLD B D , BAKER B M , et al . Understanding TCR affinity, antigen specificity, and cross-reactivity to improve TCR gene-modified T cells for cancer immunotherapy [J ] . Cancer Immunol Immunother , 2019 , 68 ( 11 ): 1881 - 1889 . DOI: 10.1007/s00262-019-02401-0 http://doi.org/10.1007/s00262-019-02401-0

SANDERSON J P , CROWLEY D J , WIEDERMANN G E , et al . Preclinical evaluation of an affinity-enhanced MAGE-A4-specific T-cell receptor for adoptive T-cell therapy [J ] . Oncoimmunology , 2020 , 9 ( 1 ): 1682381 . DOI: 10.1080/2162402X.2019.1682381 http://doi.org/10.1080/2162402X.2019.1682381 https://www.tandfonline.com/doi/full/10.1080/2162402X.2019.1682381 https://www.tandfonline.com/doi/full/10.1080/2162402X.2019.1682381

KHONG H T , WANG Q J , ROSENBERG S A . Identification of multiple antigens recognized by tumor-infiltrating lymphocytes from a single patient: tumor escape by antigen loss and loss of MHC expression [J ] . J Immunother , 2004 , 27 ( 3 ): 184 - 190 . DOI: 10.1097/00002371-200405000-00002 http://doi.org/10.1097/00002371-200405000-00002

NATHAN P , HASSEL J C , RUTKOWSKI P , et al . Overall survival benefit with tebentafusp in metastatic uveal melanoma [J ] . N Engl J Med , 2021 , 385 ( 13 ): 1196 - 1206 . DOI: 10.1056/NEJMoa2103485 http://doi.org/10.1056/NEJMoa2103485 http://www.nejm.org/doi/10.1056/NEJMoa2103485 http://www.nejm.org/doi/10.1056/NEJMoa2103485

WALKER A J , MAJZNER R G , ZHANG L , et al . Tumor antigen and receptor densities regulate efficacy of a chimeric antigen receptor targeting anaplastic lymphoma kinase [J ] . Mol Ther , 2017 , 25 ( 9 ): 2189 - 2201 . DOI: S1525-0016(17)30270-8 http://doi.org/S1525-0016(17)30270-8

ROBINSON J , HALLIWELL J A , HAYHURST J D , et al . The IPD and IMGT/HLA database: allele variant databases [J ] . Nucleic Acids Res , 2015 , 43 (Database issue): D423 - D431 . DOI: 10.1093/nar/gku1161 http://doi.org/10.1093/nar/gku1161 http://academic.oup.com/nar/article/43/D1/D423/2438496/The-IPD-and-IMGTHLA-database-allele-variant http://academic.oup.com/nar/article/43/D1/D423/2438496/The-IPD-and-IMGTHLA-database-allele-variant

GONZALEZ-GALARZA F F , MCCABE A , SANTOS E J M D , et al . Allele frequency net database (AFND) 2020 update: gold-standard data classification, open access genotype data and new query tools [J ] . Nucleic Acids Res , 2020 , 48 ( D1 ): D783 - D788 .

GARETTO S , SARDI C , MARTINI E , et al . Tailored chemokine receptor modification improves homing of adoptive therapy T cells in a spontaneous tumor model [J ] . Oncotarget , 2016 , 7 ( 28 ): 43010 - 43026 . DOI: 10.18632/oncotarget.9280 http://doi.org/10.18632/oncotarget.9280

IDORN M , SKADBORG S K , KELLERMANN L , et al . Chemokine receptor engineering of T cells with CXCR2 improves homing towards subcutaneous human melanomas in xenograft mouse model [J ] . Oncoimmunology , 2018 , 7 ( 8 ): e1450715 .

HU J M , SUN C , BERNATCHEZ C , et al . T-cell homing therapy for reducing regulatory T cells and preserving effector T-cell function in large solid tumors [J ] . Clin Cancer Res , 2018 , 24 ( 12 ): 2920 - 2934 . DOI: 10.1158/1078-0432.CCR-17-1365 http://doi.org/10.1158/1078-0432.CCR-17-1365

ADACHI K , KANO Y , NAGAI T , et al . IL-7 and CCL19 expression in CAR-T cells improves immune cell infiltration and CAR-T cell survival in the tumor [J ] . Nat Biotechnol , 2018 , 36 ( 4 ): 346 - 351 . DOI: 10.1038/nbt.4086 http://doi.org/10.1038/nbt.4086

FRAIETTA J A , LACEY S F , ORLANDO E J , et al . Author correction: determinants of response and resistance to CD19 chimeric antigen receptor (CAR) T cell therapy of chronic lymphocytic leukemia [J ] . Nat Med , 2021 , 27 ( 3 ): 561 . DOI: 10.1038/s41591-021-01248-2 http://doi.org/10.1038/s41591-021-01248-2

BECHMAN N , MAHER J . Lymphodepletion strategies to potentiate adoptive T-cell immunotherapy-what are we doing; where are we going ?[J ] . Expert Opin Biol Ther , 2021 , 21 ( 5 ): 627 - 637 . DOI: 10.1080/14712598.2021.1857361 http://doi.org/10.1080/14712598.2021.1857361 https://www.tandfonline.com/doi/full/10.1080/14712598.2021.1857361 https://www.tandfonline.com/doi/full/10.1080/14712598.2021.1857361

CHEN J , SUN H W , YANG Y Y , et al . Reprogramming immunosuppressive myeloid cells by activated T cells promotes the response to anti-PD-1 therapy in colorectal cancer [J ] . Signal Transduct Target Ther , 2021 , 6 ( 1 ): 4 .

KIM J , KANG S , KIM K W , et al . Nanoparticle delivery of recombinant IL-2 (BALLkine-2) achieves durable tumor control with less systemic adverse effects in cancer immunotherapy [J ] . Biomaterials , 2022 , 280 : 121257 . DOI: 10.1016/j.biomaterials.2021.121257 http://doi.org/10.1016/j.biomaterials.2021.121257 https://linkinghub.elsevier.com/retrieve/pii/S0142961221006141 https://linkinghub.elsevier.com/retrieve/pii/S0142961221006141

SAKAI T , TERAKURA S , MIYAO K , et al . Artificial T cell adaptor molecule-transduced TCR-T cells demonstrated improved proliferation only when transduced in a higher intensity [J ] . Mol Ther Oncolytics , 2020 , 18 : 613 - 622 . DOI: 10.1016/j.omto.2020.08.014 http://doi.org/10.1016/j.omto.2020.08.014 https://linkinghub.elsevier.com/retrieve/pii/S2372770520301315 https://linkinghub.elsevier.com/retrieve/pii/S2372770520301315

ROTH T L , LI P J , BLAESCHKE F , et al . Pooled knockin targeting for genome engineering of cellular immunotherapies [J ] . Cell , 2020 , 181 ( 3 ): 728 - 744 .e21. DOI: S0092-8674(20)30332-9 http://doi.org/S0092-8674(20)30332-9

MARTINEZ M , MOON E K . CAR T cells for solid tumors: New strategies for finding, infiltrating, and surviving in the tumor microenvironment [J ] . Front Immunol , 2019 , 10 : 128 . DOI: 10.3389/fimmu.2019.00128 http://doi.org/10.3389/fimmu.2019.00128

NALAWADE S A , SHAFER P , BAJGAIN P , et al . Selectively targeting myeloid-derived suppressor cells through TRAIL receptor 2 to enhance the efficacy of CAR T cell therapy for treatment of breast cancer [J ] . J Immunother Cancer , 2021 , 9 ( 11 ): e003237 . DOI: 10.1136/jitc-2021-003237 http://doi.org/10.1136/jitc-2021-003237 https://jitc.bmj.com/lookup/doi/10.1136/jitc-2021-003237 https://jitc.bmj.com/lookup/doi/10.1136/jitc-2021-003237

LIN S H , CHENG L , YE W , et al . Chimeric CTLA4-CD28-CD3z T cells potentiate antitumor activity against CD80/CD86-positive B cell malignancies [J ] . Front Immunol , 2021 , 12 : 642528 . DOI: 10.3389/fimmu.2021.642528 http://doi.org/10.3389/fimmu.2021.642528 https://www.frontiersin.org/articles/10.3389/fimmu.2021.642528/full https://www.frontiersin.org/articles/10.3389/fimmu.2021.642528/full

NEWICK K , O'BRIEN S , MOON E , et al . CAR T cell therapy for solid tumors [J ] . Annu Rev Med , 2017 , 68 : 139 - 152 . DOI: 10.1146/annurev-med-062315-120245 http://doi.org/10.1146/annurev-med-062315-120245

D’ALOIA M M , ZIZZARI I G , SACCHETTI B , et al . CAR-T cells: the long and winding road to solid tumors [J ] . Cell Death Dis , 2018 , 9 ( 3 ): 282 . DOI: 10.1038/s41419-018-0278-6 http://doi.org/10.1038/s41419-018-0278-6

ZHANG B L , QIN D Y , MO Z M , et al . Hurdles of CAR-T cell-based cancer immunotherapy directed against solid tumors [J ] . Sci China Life Sci , 2016 , 59 ( 4 ): 340 - 348 . DOI: 10.1007/s11427-016-5027-4 http://doi.org/10.1007/s11427-016-5027-4 http://link.springer.com/10.1007/s11427-016-5027-4 http://link.springer.com/10.1007/s11427-016-5027-4

YE B X , SMERIN D , GAO Q P , et al . High-throughput sequencing of the immune repertoire in oncology: applications for clinical diagnosis, monitoring, and immunotherapies [J ] . Cancer Lett , 2018 , 416 : 42 - 56 . DOI: S0304-3835(17)30789-9 http://doi.org/S0304-3835(17)30789-9

CHEN F J , ZOU Z Y , DU J , et al . Neoantigen identification strategies enable personalized immunotherapy in refractory solid tumors [J ] . J Clin Invest , 2019 , 129 ( 5 ): 2056 - 2070 . DOI: 10.1172/JCI99538 http://doi.org/10.1172/JCI99538

JOGLEKAR A V , LEONARD M T , JEPPSON J D , et al . T cell antigen discovery via signaling and antigen-presenting bifunctional receptors [J ] . Nat Methods , 2019 , 16 ( 2 ): 191 - 198 . DOI: 10.1038/s41592-018-0304-8 http://doi.org/10.1038/s41592-018-0304-8

CHEN X J , PONCETTE L , BLANKENSTEIN T . Human TCR-MHC coevolution after divergence from mice includes increased nontemplate-encoded CDR3 diversity [J ] . J Exp Med , 2017 , 214 ( 11 ): 3417 - 3433 . DOI: 10.1084/jem.20161784 http://doi.org/10.1084/jem.20161784 https://rupress.org/jem/article/214/11/3417/42268/Human-TCR-MHC-coevolution-after-divergence-from https://rupress.org/jem/article/214/11/3417/42268/Human-TCR-MHC-coevolution-after-divergence-from

KRSHNAN L , PARK S , IM W , et al . A conserved αβ transmembrane interface forms the core of a compact T-cell receptor-CD3 structure within the membrane [J ] . Proc Natl Acad Sci U S A , 2016 , 113 ( 43 ): E6649 - E6658 .

KNIES D , KLOBUCH S , XUE S A , et al . An optimized single chain TCR scaffold relying on the assembly with the native CD3-complex prevents residual mispairing with endogenous TCRs in human T-cells [J ] . Oncotarget , 2016 , 7 ( 16 ): 21199 - 21221 . DOI: 10.18632/oncotarget.8385 http://doi.org/10.18632/oncotarget.8385

ARMISTEAD P M . Cellular therapy against public neoantigens [J ] . J Clin Invest , 2019 , 129 ( 2 ): 506 - 508 . DOI: 10.1172/JCI126116 http://doi.org/10.1172/JCI126116

LU Y C , ZHENG Z L , LOWERY F J , et al . Direct identification of neoantigen-specific TCRs from tumor specimens by high-throughput single-cell sequencing [J ] . J Immunother Cancer , 2021 , 9 ( 7 ): e002595 . DOI: 10.1136/jitc-2021-002595 http://doi.org/10.1136/jitc-2021-002595 https://jitc.bmj.com/lookup/doi/10.1136/jitc-2021-002595 https://jitc.bmj.com/lookup/doi/10.1136/jitc-2021-002595

LI S R , HUO F Y , WANG H Q , et al . Recent advances in porous nanomaterials-based drug delivery systems for cancer immunotherapy [J ] . J Nanobiotechnology , 2022 , 20 ( 1 ): 277 . DOI: 10.1186/s12951-022-01489-4 http://doi.org/10.1186/s12951-022-01489-4

CADILHA B L , BENMEBAREK M R , DORMAN K , et al . Combined tumor-directed recruitment and protection from immune suppression enable CAR T cell efficacy in solid tumors [J ] . Sci Adv , 2021 , 7 ( 24 ): eabi5781 . DOI: 10.1126/sciadv.abi5781 http://doi.org/10.1126/sciadv.abi5781 https://www.science.org/doi/10.1126/sciadv.abi5781 https://www.science.org/doi/10.1126/sciadv.abi5781

EVGIN L , KOTTKE T , TONNE J , et al . Oncolytic virus-mediated expansion of dual-specific CAR T cells improves efficacy against solid tumors in mice [J ] . Sci Transl Med , 2022 , 14 ( 640 ): eabn2231 . DOI: 10.1126/scitranslmed.abn2231 http://doi.org/10.1126/scitranslmed.abn2231 https://www.science.org/doi/10.1126/scitranslmed.abn2231 https://www.science.org/doi/10.1126/scitranslmed.abn2231

PARKHURST M , GROS A , PASETTO A , et al . Isolation of T-cell receptors specifically reactive with mutated tumor-associated antigens from tumor-infiltrating lymphocytes based on CD137 expression [J ] . Clin Cancer Res , 2017 , 23 ( 10 ): 2491 - 2505 . DOI: 10.1158/1078-0432.CCR-16-2680 http://doi.org/10.1158/1078-0432.CCR-16-2680

MARCU A , BICHMANN L , KUCHENBECKER L , et al . HLA Ligand Atlas: a benign reference of HLA-presented peptides to improve T-cell-based cancer immunotherapy [J ] . J Immunother Cancer , 2021 , 9 ( 4 ): e002071 . DOI: 10.1136/jitc-2020-002071 http://doi.org/10.1136/jitc-2020-002071 https://jitc.bmj.com/lookup/doi/10.1136/jitc-2020-002071 https://jitc.bmj.com/lookup/doi/10.1136/jitc-2020-002071

HU Z D , ZHU L Y , WANG J , et al . Immune signature of enhanced functional avidity CD8 + T cells in vivo induced by vaccinia vectored vaccine [J ] . Sci Rep , 2017 , 7 : 41558 . DOI: 10.1038/srep41558 http://doi.org/10.1038/srep41558

ALBA J , D‘ABRAMO M . The full model of the pMHC-TCR-CD3 complex: a structural and dynamical characterization of bound and unbound states [J ] . Cells , 2022 , 11 ( 4 ): 668 . DOI: 10.3390/cells11040668 http://doi.org/10.3390/cells11040668 https://www.mdpi.com/2073-4409/11/4/668 https://www.mdpi.com/2073-4409/11/4/668

HE W H , CAO Z L , MAO F F , et al . Modification of three amino acids in sodium taurocholate cotransporting polypeptide renders mice susceptible to infection with hepatitis D virus in vivo [J ] . J Virol , 2016 , 90 ( 19 ): 8866 - 8874 . DOI: 10.1128/JVI.00901-16 http://doi.org/10.1128/JVI.00901-16 https://journals.asm.org/doi/10.1128/JVI.00901-16 https://journals.asm.org/doi/10.1128/JVI.00901-16

CAO Y Q , LU W Y , SUN R , et al . Anti-CD19 chimeric antigen receptor T cells in combination with nivolumab are safe and effective against relapsed/refractory B-cell non-Hodgkin lymphoma [J ] . Front Oncol , 2019 , 9 : 767 . DOI: 10.3389/fonc.2019.00767 http://doi.org/10.3389/fonc.2019.00767

Views

2318

下载量

CSCD

Alert me when the article has been cited

提交

Tools

Publicity Resources

Targeted therapy and immunotherapy combined with chemotherapy bring effective response to AFP positive colon cancer patients: a case report and literature review

Mechanism study of MYC promoting proliferation and metastasis in prostate cancer by targeting CD47

MDT consensus on immunotherapy for locally advanced head and neck squamous cell carcinoma (2025 edition)

Research status and progress of third-line treatment for metastatic colorectal cancer

Phase Ⅰ study of intrathecal pemetrexed combined with programmed death-1 inhibitor for leptomeningeal metastases from solid tumors

Related Author

LIU Miao

LI Jinze

WU Chensi

ZHANG Fengbin

GAO Hongsheng

ZHANG Ruixing

Hao LIU

Junjie SU

Related Institution

Department of Pathology, the Fourth Hospital of Hebei Medical University

Department of Gastroenterology, the Fourth Hospital of Hebei Medical University

Department of Urology, The First Affiliated Hospital and College of Clinical Medicine of Henan University of Science and Technology

College of Basic Medicine and Forensic Medicine, Henan University of Science and Technology

Committee of Head and Neck Cancer, Chinese Society of Clinical Oncology

AI问答

⁰